Joseph Reilly - Ardelyx Senior Officer
| ARDX Stock | USD 5.69 0.34 6.36% |
Executive
Joseph Reilly is Senior Officer of Ardelyx
| Age | 51 |
| Address | 400 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 510 745 1700 |
| Web | https://www.ardelyx.com |
Ardelyx Management Efficiency
The company has return on total asset (ROA) of (0.1218) % which means that it has lost $0.1218 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4154) %, meaning that it created substantial loss on money invested by shareholders. Ardelyx's management efficiency ratios could be used to measure how well Ardelyx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. At this time, Ardelyx's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 47.1 M in 2024, whereas Total Assets are likely to drop slightly above 180.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lee Flowers | HCW Biologics | 78 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Alexander Constan | Ikena Oncology | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Bob Lally | Ikena Oncology | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Caroline MD | Ikena Oncology | 52 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| David MS | Ikena Oncology | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Leesa Gentry | RenovoRx | 54 | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.12 |
Ardelyx Leadership Team
Elected by the shareholders, the Ardelyx's board of directors comprises two types of representatives: Ardelyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ardelyx. The board's role is to monitor Ardelyx's management team and ensure that shareholders' interests are well served. Ardelyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ardelyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Esq, Chief Secretary | ||
| Susan Rodriguez, Chief Officer | ||
| Michael Raab, CEO and President and Director | ||
| Elizabeth Grammer, Vice President General Counsel | ||
| Joseph Reilly, Senior Officer | ||
| CPA MST, CFO Treasurer | ||
| Robert Felsch, Senior Officer | ||
| Caitlin Lowie, Vice Relations | ||
| David Rosenbaum, Sr. VP of Drug Devel. | ||
| Kimia Keshtbod, Mang Relations | ||
| Robert Blanks, Chief Officer | ||
| Mike Kelliher, Executive Strategy | ||
| Karen Harrigan, Director Devel | ||
| Charon Sr, Chief Officer | ||
| Dan Pavicich, Director Devel | ||
| MPH MD, Chief Officer |
Ardelyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ardelyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 236.85 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 61.46 % | ||||
| Number Of Shares Shorted | 23.31 M | ||||
| Price To Earning | (2.11) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ardelyx Stock Analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.